When exploring therapeutic options against the described molecular alterations, we observed that only one drug, sotorasib (AMG 510) has been approved for the treatment of K-RAS G12C mutated NSCLC, with another one, adagrasib in its late clinical development stage. Here, KRAS is linked to non-small cell lung carcinoma.